Angiotensin receptor-neprilysin inhibition with LCZ696: A novel approach for the treatment of heart failure

Drug Discovery Today: Therapeutic Strategies

Volumn 9, Issue 4, 2012, Pages

  Langenickel, Thomas H ^a   Dole, William P ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ANGIOTENSIN RECEPTOR; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; RENIN; VALSARTAN;

ARTICLE; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA RENIN ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BALANCE; SURVIVAL;

EID: 84900835466     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2013.11.002     Document Type: Review

References (55)

1. S.A. Hunt et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol. 53 2009 e1 e90
2. A.S. Go et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association Circulation 127 2013 e6 e245
3. H. Krum, and R.E. Gilbert Demographics and concomitant disorders in heart failure Lancet 362 2003 147 158
4. J.J. McMurray et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur. Heart J. 33 2012 1787 1847
5. S. Mangiafico et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics Eur. Heart J. 34 2013 886 893
6. R.W. Schrier et al. Therapy of heart failure Kidney Int. 57 2000 1418 1425
7. U.C. Brewster et al. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states Am. J. Med. Sci. 326 2003 15 24
8. E.R. Levin et al. Natriuretic peptides N. Engl. J. Med. 339 1998 321 328
9. G. Boerrigter, and J.C. Burnett Jr. Recent advances in natriuretic peptides in congestive heart failure Expert Opin. Investig. Drugs 13 2004 643 652
10. A.J. Kenny et al. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11 Biochem. J. 291 1993 83 88
11. A. Martinez-Rumayor et al. Biology of the natriuretic peptides Am. J. Cardiol. 101 Suppl 2008 3A 8A
12. S. Nathisuwan, and R.L. Talbert A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure Pharmacotherapy 22 2002 27 42
13. L.S. Marcus et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial Circulation 94 1996 3184 3189
14. S. Rubattu et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases Am. J. Hypertens. 21 2008 733 741
15. D. Hayashi et al. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1 Biochem. Biophys. Res. Commun. 322 2004 310 319
16. Y. Izumiya et al. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling Int. J. Vasc. Med. 2012 246058 10.1155/2012/246058
17. C. Moro, and M. Lafontan Natriuretic peptides and cGMP signaling control of energy homeostasis Am. J. Physiol. Heart Circ. Physiol. 304 2013 H358 H368
18. P. Welsh, and J.J. McMurray B-type natriuretic peptide and glycaemia: an emerging metabolic pathway? Diabetologia 55 2012 1240 1243
19. S.C. Souza et al. Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK Biochem. Biophys. Res. Commun. 410 2011 398 403
20. A.L. Birkenfeld et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans Diabetes 57 2008 3199 3204
21. N.M. Borradaile, and J.E. Schaffer Lipotoxicity in the heart Curr. Hypertens. Rep. 7 2005 412 417
22. R. Sarzani et al. Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth Int. J. Obes. 32 2008 259 267
23. V. Cannone et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community J. Am. Coll. Cardiol. 58 2011 629 636
24. W.L. Miller et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure Circ. Heart Fail. 4 2013 355 360
25. J. Fielitz et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure Circulation 105 2002 286 289
26. A. Charloux et al. Mechanisms of renal hyporesponsiveness to ANP in heart failure Eur. J. Clin. Invest. 33 2003 769 778
27. C.J. Ferro et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 1998 2323 2330
28. P.A. Deddish et al. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin (1-7) and keto-ACE Hypertension 31 1998 912 917
29. S.V. Pinheiro, and A.C. Simões E Silva Angiotensin converting enzyme 2, angiotensin-(1-7), and receptor MAS axis in the kidney Int. J. Hypertens. 22 2012 224 233
30. J.B. Byrd et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema Hypertension 51 2008 141 147
31. A.M. Richards et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II J. Hypertens. 11 1993 407 416
32. D.B. Northridge et al. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure Am. Heart J. 138 1999 1149 1157
33. A.S. Westheim et al. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure J. Am. Coll. Cardiol. 34 1999 1794 1801
34. D.E. Newby et al. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition Eur. Heart J. 19 1998 1808 1813
35. K.B. Margulies et al. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure J. Clin. Invest. 88 1991 1636 1642
36. M. Packer et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
37. R.M. Fryer et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br. J. Pharmacol. 153 2008 947 955
38. A.L. Cilia La Corte et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema Hum. Mutat. 32 2011 1326 1331
39. S. Toh et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system Arch. Intern. Med. 172 2012 1582 1589
40. D.J. Campbell et al. Losartan increases bradykinin levels in hypertensive humans Circulation 111 2005 315 320
41. Q. Pu et al. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP J. Hypertens. 26 2008 322 333
42. T.G. Von Lueder et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure Circ. Heart Fail. 6 2013 594 605
43. L.G. Hegde et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat J. Cardiovasc. Pharmacol. 57 2011 495 504
44. L. Feng et al. LCZ696: a dual-acting sodium supramolecular complex Tetrahedron Lett. 53 2012 275 276
45. J. Gu et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J. Clin. Pharmacol. 50 2010 401 414
46. Z. Kobalava et al. Blood pressure lowering and natriuretic effects of LCZ696 in patients with hypertension: a randomized, double-blind, controlled, crossover study Poster presented at 28th Annual Scientific Meeting and Exposition of the American Society of Hypertension (ASH) 15-18 May 2013, San Francisco, CA, USA 2013
47. L.M. Ruilope et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
48. N. Sun et al. Efficacy and safety of three doses of LCZ696 in Asian hypertensive patients J. Hypertens. 29 e.Suppl. B 2011 e18, G-008
49. Z. Kobalava et al. Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP Eur. Heart J. 32 Abstract Suppl. 2011 784 785
50. P. Jordaan et al. Changes in RAAS (renin angiotensin aldosterone system) biomarkers in patients with stable chronic heart failure following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment SA Heart 8 2011 236
51. J.J. McMurray et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur. J. Heart Fail 15 2013 1062 1073
52. S.D. Solomon et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
53. M. Komajda et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) Circ. Heart Fail. 4 2011 27 35
54. A. Brenyo et al. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) J. Am. Coll. Cardiol. 58 2011 1682 1689
55. M.R. Zile et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction Circulation 124 2011 2491 2501